Cancer Biology Research’s Post

Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies https://lnkd.in/exUPwUxp

Our latest publication is out 🎉 and a dream came true! In this review we thoroughly dissect the immunomodulatory role of CAFs within the tumor microenvironment, with a particular focus on the effects exerted by CAF-derived extracellular matrix (ECM) remodeling in controlling T cell states and localization in solid tumors. Check it out @ https://lnkd.in/dg99cJr8

Ophthopedia Update:RB1 CIRCULATING TUMOR DNA IN THE BLOOD OF PATIENTS WITH RETINOBLASTOMA INCREASES IN UNTREATED PATIENTS: Purpose: Circulating tumor DNA (ctDNA) in plasma has been identified in many cancers, including retinoblastoma at diagnosis. It has previously been shown that with treatment (enucleation or ophthalmic artery chemosurgery), all ctDNA disappears; if there is persistent plasma ctDNA after treatment, metastases develop. The purpose of this study was to determine how the ctDNA RB1 variant allele frequency changes in patients with retinoblastoma who have delayed treatment. Methods: Circulating tumor DNA RB1 was detected, and variant allele frequency was measured at diagnosis and again before any intervention at some time later ranging from 2 days to 28 days. Results: Four patients with five ctDNA RB1 mutations were detected at diagnosis, and variant allele frequency was increased on reevaluation of the same RB1 mutations in ctDNA. Conclusion: In this small cohort, every patient (4) and every RB1 mutation (5) plasma level VAF% increased when measured at two time periods before treatment was initiated suggesting that growing tumors demonstrate increasing plasma ctDNA. #Ophthotwitter #Ophthalmology #Retina

New Review!🍷 Focusing on #CD8+ T-cell phenotypes: improving solid tumor therapy ----------------- Vigorous CD8+ T cells play a crucial role in recognizing tumor cells and combating solid tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain the activity in the “rejection” of solid tumor microenvironment, are major concerns. Recent advances in understanding of the immunological trajectory and lifespan of CD8+ T cells have provided guidance for the design of more optimal anti-tumor immunotherapy regimens. Here, Ding et al review the newly discovered methods to enhance the function of CD8+ T cells against solid tumors, focusing on optimizing T cell receptor (TCR) expression, improving antigen recognition by engineered T cells, enhancing signal transduction of the TCR-CD3 complex, inducing the homing of polyclonal functional T cells to tumors, reversing T cell exhaustion under chronic antigen stimulation, and reprogramming the energy and metabolic pathways of T cells. Look here👇 https://lnkd.in/daMcfb9r #Immunotherapy #GeneEditing #ImmuneReprogramming #MetabolicReprogramming IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Neoadjuvant chemo-immunotherapy is superior to neoadjuvant chemotherapy across surgical, pathological and efficacy outcomes for patients with resectable NSCLC and improves EFS in patients with tumor PD-L1 <1%. https://ja.ma/4bGnTVv

📃Scientific paper: “Bone in the penis” or fasciitis ossificans of the penis – a first time description of a pseudo-tumor at an extraordinary site Abstract: Background Fasciitis ossificans is a rare subtype of nodular fasciitis, a benign soft tissue tumor with reactive characteristics. Due to its rapid growth, it is often misdiagnosed as a malignant tumor. While fasciitis ossificans commonly originates from the subcutaneous tissue and can appear throughout the body, it may also arise from extraordinary sites. Case presentation We report the first-ever documented case of fasciitis ossificans arising from the penis in a male patient who presented with a tumor on the glans penis. The tumor was surgically resected due to suspicion of penile cancer. Initial histopathological analysis led to a misdiagnosis of squamous cell carcinoma. However, pathological consultation ultimately confirmed the diagnosis of fasciitis ossificans of the penis originating from the glans penis by demonstrating ossification. Conclusion This case underscores the importance of considering fasciitis ossificans in the differential diagnosis of soft tissue tumors, even in unusual locations such as penile soft tissue. Continued on ES/IODE ➡️ https://etcse.fr/CmskT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: “Bone in the penis” or fasciitis ossificans of the penis – a first time description of a pseudo-tumor at an extraordinary site Abstract: Background Fasciitis ossificans is a rare subtype of nodular fasciitis, a benign soft tissue tumor with reactive characteristics. Due to its rapid growth, it is often misdiagnosed as a malignant tumor. While fasciitis ossificans commonly originates from the subcutaneous tissue and can appear throughout the body, it may also arise from extraordinary sites. Case presentation We report the first-ever documented case of fasciitis ossificans arising from the penis in a male patient who presented with a tumor on the glans penis. The tumor was surgically resected due to suspicion of penile cancer. Initial histopathological analysis led to a misdiagnosis of squamous cell carcinoma. However, pathological consultation ultimately confirmed the diagnosis of fasciitis ossificans of the penis originating from the glans penis by demonstrating ossification. Conclusion This case underscores the importance of considering fasciitis ossificans in the differential diagnosis of soft tissue tumors, even in unusual locations such as penile soft tissue. Continued on ES/IODE ➡️ https://etcse.fr/CmskT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Important review by William Y. Kim and Tracy L. Rose, MD, MPH, University of North Carolina at Chapel Hill School of Medicine on renal cell carcinoma one of the top 10 most common cancers among men and women in the US. Although common, it is often incidentally diagnosed. In the review, Billy Kim points to new treatment options related to immune checkpoint inhibitors and tyrosine kinase inhibitors. The Kim Lab focuses on the role of genetic events related to initiation and progression of renal cell carcinoma and bladder. His work is an excellent example of how University of North Carolina at Chapel Hill researchers are leveraging next gen sequencing techniques, in this case sequencing of tumors to identify genomic changes that drive cancer, with the ultimate goal of identifying therapeutic avenues to prevent and treat cancer. UNC Research at its best. https://lnkd.in/eCRbVay3

A #clinicaltrial has shown that a new drug combination utilized BEFORE surgery completely eliminated or shrunk #melanoma tumors in 70% of trial participants. The phase II clinical trial, #NeoACTIVATE, enrolled patients with stage 3 melanoma; trial results were shared in a study published in Nature Communications. https://lnkd.in/ed9PGJfR "We saw that about two-thirds of the patients in one arm of the trial had no remaining tumor at all at the time of their surgery," said Matthew S. Block, M.D., Ph.D., leader of the Stand Up To Cancer (SU2C) Catalyst Research Team that ran the clinical trial, immunologist and a medical oncologist at the Mayo Clinic Comprehensive Cancer Center and senior author of the study. The new drug therapy tested in this clinical trial involved two combinations of targeted therapy and #immunotherapy before surgery, and more immunotherapy after surgery. This was the first clinical trial to explore using the combination of targeted therapy and immunotherapy before surgery in patients with and without the type of melanoma that has a mutation in a specific #gene called the #BRAF gene. About one half of people with melanoma have the BRAF #mutation. Cancer experts have found certain targeted therapies work especially well to counter that mutation. https://lnkd.in/ed9PGJfR

📃Scientific paper: “Bone in the penis” or fasciitis ossificans of the penis – a first time description of a pseudo-tumor at an extraordinary site Abstract: Background Fasciitis ossificans is a rare subtype of nodular fasciitis, a benign soft tissue tumor with reactive characteristics. Due to its rapid growth, it is often misdiagnosed as a malignant tumor. While fasciitis ossificans commonly originates from the subcutaneous tissue and can appear throughout the body, it may also arise from extraordinary sites. Case presentation We report the first-ever documented case of fasciitis ossificans arising from the penis in a male patient who presented with a tumor on the glans penis. The tumor was surgically resected due to suspicion of penile cancer. Initial histopathological analysis led to a misdiagnosis of squamous cell carcinoma. However, pathological consultation ultimately confirmed the diagnosis of fasciitis ossificans of the penis originating from the glans penis by demonstrating ossification. Conclusion This case underscores the importance of considering fasciitis ossificans in the differential diagnosis of soft tissue tumors, even in unusual locations such as penile soft tissue. Continued on ES/IODE ➡️ https://etcse.fr/CmskT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.